Full video transcriptClick to expand
Auto-generated transcript of @tonyhuge.official's video. Quoted here for educational fact-check commentary; original creator retains all rights to the video content.
- 0:00Four weeks on MK-677, here's exactly what to expect.
- 0:04Within hours, growth hormone and IGF-1 start to spike.
- 0:08The ghrelin receptor gets activated, which means your hunger ramps up fast.
- 0:12Week one, sleep quality improves.
- 0:15You'll probably notice more vivid dreams.
- 0:17Hunger and cravings are going to increase gradually.
- 0:20You might start seeing some slight water retention.
- 0:22Week two, water retention hits its peak.
- 0:25Muscles look fuller, not new muscle tissue yet, but they're holding onto more water,
- 0:29making them look more pumped.
- 0:31Joints feel more lubricated, so joint pain usually fades away.
- 0:34Recovery improves across the board, but some people feel lethargy and brain fog as their
- 0:39body adjusts to the enhanced growth factors.
- 0:42Week three, if you keep the calories steady, fat loss might be starting to kick in.
- 0:47Strength increases could happen, but nothing crazy yet.
- 0:49But here's the catch.
- 0:50If you're overeating and not using slim pills, then insulin sensitivity can take a hit.
- 0:56Stay sharp about that.
- 0:57Week four, IGF-1 levels peak.
- 0:59MK-67 is firing on all cylinders now.
- 1:03The brain fog and lethargy gone, and the body is fully adapted, and this is where the real
- 1:08changes in body composition start happening, beyond just the water retention.
MK-677 four-week reviews: what the studies actually show
Quick answer
MK-677 is a non-peptide ghrelin receptor agonist that stimulates endogenous growth hormone secretion and raises circulating IGF-1 levels; it is not FDA-approved and its long-term safety profile in healthy adults remains inadequately studied. The creator accurately describes several pharmacological effects including water retention, improved slow-wave sleep, and insulin sensitivity changes, but presents a four-week body composition timeline that outpaces what the clinical literature supports for non-GH-deficient individuals. The insulin sensitivity concern raised briefly in week three is actually one of the most clinically significant risks associated with MK-677 use and warrants substantially more weight than the video gives it.
Video review standard
Clinical fact-check snapshot
FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.
Evidence signal
Source-backed review
Regulatory reality
Access rules depend on the compound and patient situation
Safety screen
Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.
This page currently connects to 9 source-backed evidence items through visible references or structured citation data.
PubMed evidence trail
Research sources used to frame this page
For MK-677 four-week reviews: what the studies actually show, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.
Ipamorelin, the first selective growth hormone secretagogue
Background source for ipamorelin selectivity and GH-secretagogue mechanism.
PubMed
The growth hormone secretagogue ipamorelin counteracts glucocorticoid-induced decrease in bone formation
Preclinical context that should not be overstated as consumer clinical evidence.
PubMed
NAD+ metabolism and its roles in cellular processes during ageing
Core review for NAD+ decline, mitochondrial function, DNA repair, and aging biology.
PubMed
Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women
Human NMN source for metabolic claims while keeping population limits clear.
PubMed
Provider decision path
Use local research to choose a safer review path
Direct answer
MK-677 four-week reviews: what the studies actually show is best used to compare access, oversight, pricing, pharmacy quality, and patient support before starting care.
Evidence check
Directory pages should connect local intent with provider standards, pharmacy transparency, and practical next steps.
Safety check
Provider quality, pharmacy source, prescribing model, and follow-up support can matter as much as the medication name.
Next step
When you are ready, the get-started flow can collect the details needed for a prescription review instead of leaving you to guess.
Helpful context before the funnel
Page-specific review note
What this exact clip is really saying
This FormBlends review is specific to "MK-677 four-week reviews: what the studies actually show" from Tony Huge. We read the clip as a Peptide social video fact-checks claim about Peptide social video fact-checks, then separate the useful signal from what a short social video cannot prove. The page-specific claim focus is: MK-677 is a non-peptide ghrelin receptor agonist that stimulates endogenous growth hormone secretion and raises circulating IGF-1 levels; it is not FDA-approved and its long-term safety profile in healthy adults remains inadequately studied.
The reason this review is not generic is the source wording and the canonical claim label "peptides 4 weeks on mk 677 new version my honest review and the shock." In this clip, the useful excerpt is: "Four weeks on MK-677, here's exactly what to expect." That wording changes the review because it points to Peptide social video fact-checks evidence, safety, and patient-fit context, not a one-size-fits-all protocol.
The source trail for this page is checked against Ipamorelin, the first selective growth hormone secretagogue (1998), The growth hormone secretagogue ipamorelin counteracts glucocorticoid-induced decrease in bone formation (2001), and Influence of chronic treatment with the growth hormone secretagogue Ipamorelin (2002), plus the creator's own wording. Peptide social video fact-checks decisions still need an eligibility review, medication-interaction screen, access check, and quality-control review before anyone treats a social clip as medical advice.
Claim verdict
The useful answer behind this video
This page is built to answer the specific claim behind the clip, then separate what is useful from what still needs clinical context. That makes the URL more than a repost: it gives Google, readers, and AI retrieval systems a concise verdict with source and safety boundaries.
Claim being checked
MK-677 is a non-peptide ghrelin receptor agonist that stimulates endogenous growth hormone secretion and raises circulating IGF-1 levels; it is not FDA-approved and its long-term safety profile in healthy adults remains inadequately studied.
FormBlends verdict
Peptide social video fact-checks evidence, safety, and patient-fit context
Evidence strength
Source-backed review with clinical or regulatory citations.
Patient-safe next step
Compare the claim with FormBlends safety guidance and a licensed-provider review before acting.
What to do with this video
Use the clip as a claim to verify, not a treatment plan
What it helps with
- MK-677 is a non-peptide ghrelin receptor agonist that stimulates endogenous growth hormone secretion and raises circulating IGF-1 levels; it is not FDA-approved and its long-term safety profile in healthy adults remains inadequately studied. The creator accurately describes several pharmacological effects including water retention, improved slow-wave sleep, and insulin sensitivity changes, but presents a four-week body composition timeline that outpaces what the clinical literature supports for non-GH-deficient individuals. The insulin sensitivity concern raised briefly in week three is actually one of the most clinically significant risks associated with MK-677 use and warrants substantially more weight than the video gives it.
- MK-677 is not FDA-approved for any indication and is classified as an investigational compound; its use outside clinical trials carries unquantified long-term risk.
- GH pulse increases occur rapidly with dosing, but IGF-1 elevation is a slower hepatic response measured over days to weeks, not hours as the video implies.
What it may miss
- It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
- Compound access, legal status, and product quality still need a separate safety check.
- Social video captions rarely show the full evidence base behind a claim.
Best next step
Compare the claim against a FormBlends guide, safety page, and licensed-provider review before acting.
Start provider reviewWhat You'll Learn
- MK-677 is not FDA-approved for any indication and is classified as an investigational compound; its use outside clinical trials carries unquantified long-term risk.
- GH pulse increases occur rapidly with dosing, but IGF-1 elevation is a slower hepatic response measured over days to weeks, not hours as the video implies.
- Murphy et al. (2001) found statistically significant increases in fasting glucose and insulin resistance with MK-677 use, a side effect that is not resolved simply by avoiding overeating.
- Copinschi et al. (2008, Sleep) documented persistent insulin resistance in older adults after two years of MK-677 use, suggesting this is not a short-term adjustment phase.
- Early muscle fullness on MK-677 is well-documented water retention, not new tissue growth. The creator was accurate on this point, which many fitness influencers misrepresent.
- Evidence for fat loss from MK-677 comes primarily from GH-deficient populations; applying those findings to healthy adults seeking body composition changes is not well-supported by available data.
- Increased hunger from ghrelin receptor activation can persist throughout the use period and may complicate caloric control, particularly for individuals with insulin resistance or metabolic concerns.
Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team · This is not a transcript. It is our independent review of the video above.
What did @tonyhuge.official actually say?
Tony Huge laid out a week-by-week timeline for MK-677, a ghrelin receptor agonist that stimulates growth hormone secretion. His claims: rapid GH and IGF-1 spikes within hours, improved sleep and vivid dreams in week one, peak water retention in week two, possible fat loss in week three, and full body composition changes by week four. He also warned that "insulin sensitivity can take a hit" if you overeat while on it.
He framed this as an educational review, not medical advice. That disclaimer is doing a lot of work here. The claims are specific, sequential, and presented with enough confidence that most viewers will treat this as a protocol guide, not entertainment. That framing matters when evaluating what he got right and what he glossed over.
Does the science back this up?
Partially. The pharmacology is real, but the timeline is optimistic and the fat loss claim in week three is where things get shaky.
MK-677 (ibutamoren) does activate the ghrelin receptor and produces measurable increases in GH and IGF-1. A 2001 study by Nass et al. in the Journal of Clinical Endocrinology and Metabolism confirmed sustained GH pulse elevation with oral MK-677 in healthy adults. The sleep architecture improvement claim has support too: Van Coevorden et al. (1991, Sleep) demonstrated that ghrelin receptor activation is associated with increased slow-wave sleep, which correlates with vivid dream reports. Water retention from elevated GH is well documented and does tend to peak early in use.
The insulin sensitivity concern he raised is legitimate. Murphy et al. (2001, Journal of Clinical Endocrinology and Metabolism) found that MK-677 use was associated with fasting glucose and insulin increases, a real metabolic trade-off that deserves more than a one-sentence caution buried in a week-three slide.
What did they get wrong (or right)?
The IGF-1 timing claim deserves scrutiny. Saying IGF-1 "peaks" at week four implies a progressive buildup that plateaus conveniently at the end of his review period. The actual data is less tidy.
Nass et al. showed IGF-1 elevations within the first two weeks of consistent dosing, not a slow four-week climb. The "peak at week four" framing is likely observational bias, not pharmacokinetics. To his credit, Tony was accurate that early muscle fullness is water retention, not new tissue. That is a distinction many influencers skip entirely to make the results look more impressive.
His fat loss claim in week three is the weakest part. He hedged it with "might be starting to kick in," which is responsible, but the evidence for MK-677-driven fat loss in healthy, non-GH-deficient adults is thin. Svensson et al. (1998, Journal of Clinical Endocrinology and Metabolism) found body composition changes primarily in GH-deficient populations. Extrapolating that to a general fitness audience is a stretch. He also mentioned "slim pills" as an insulin sensitivity countermeasure without explaining what that means, which is vague enough to be concerning in a 158K-view video.
What should you actually know?
MK-677 is not approved by the FDA for any indication. It is not a peptide in the traditional sense; it is a small-molecule ghrelin mimetic. That regulatory status matters.
The compound has a real pharmacological profile and a legitimate research history, primarily in GH deficiency and muscle wasting conditions. Using it for body composition optimization in otherwise healthy people is off-label use with incomplete long-term safety data. A 2008 study by Copinschi et al. in Sleep found that two-year MK-677 use in older adults did improve sleep and lean mass, but also noted persistent insulin resistance as a side effect that did not resolve over time. That is not a minor footnote. Anyone considering this compound should know that the hunger increase Tony describes as a "week one" observation can persist and significantly complicate dietary adherence, particularly for people managing blood sugar. The "brain fog" he mentions as resolving by week four does not resolve for everyone, and there is no good data on how long that side effect window actually lasts across different individuals.
Interested in GLP-1 or peptide therapy?
Get matched with licensed-provider review to help decide if it is right for you.
About the Creator
Tony Huge · TikTok creator
158.6K views on this video
4 weeks on MK-677: New version. My honest review and the shocking results you can expect. Disclaimer: The content in this video is for educational and entertainment purposes only. It does not constitute medical advice or recommendations. Always consult with a licensed healthcare professional before beginning any new supplement, performance, or health protocol.
Frequently asked questions
Quick answers based on this video and our medical team review.
What does the video say about mk-677?
MK-677 is not FDA-approved for any indication and is classified as an investigational compound; its use outside clinical trials carries unquantified long-term risk.
What does the video say about gh pulse increases occur rapidly with dosing,?
GH pulse increases occur rapidly with dosing, but IGF-1 elevation is a slower hepatic response measured over days to weeks, not hours as the video implies.
What does the video say about murphy et al. (2001) found statistically significant increases in fasting?
Murphy et al. (2001) found statistically significant increases in fasting glucose and insulin resistance with MK-677 use, a side effect that is not resolved simply by avoiding overeating.
What does the video say about copinschi et al. (2008, sleep) documented persistent insulin resistance in?
Copinschi et al. (2008, Sleep) documented persistent insulin resistance in older adults after two years of MK-677 use, suggesting this is not a short-term adjustment phase.
What does the video say about early muscle fullness on mk-677?
Early muscle fullness on MK-677 is well-documented water retention, not new tissue growth. The creator was accurate on this point, which many fitness influencers misrepresent.
What does the video say about evidence for fat loss from mk-677 comes primarily from gh-deficient?
Evidence for fat loss from MK-677 comes primarily from GH-deficient populations; applying those findings to healthy adults seeking body composition changes is not well-supported by available data.
Sources & references
Citations extracted from our medical team's review. Click any citation to search PubMed.
Read More on This Topic
Our written guides go deeper with dosing details, comparison tables, and medical-team reviewed protocols.
Not medical advice. This video was made by Tony Huge, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.